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Introduction: Cystic Fibrosis (CF) is an autosomal recessive disorder with serious 
pulmonary and nutritional implications. Nutrition status has a direct affect on lung 
function and longevity. Screening patients for growth velocity makes it possible to 
identify patients at nutritional risk . This identification is the first step towards 
appropriate nutritional interventions . The current screening tool used for children and 
adolescents with CF is not reliable and leaves too much room for clinical judgment. It is 
for this reason that a new screening tool was developed. Methods: The Cystic Fibrosis 
Foundation established a panel of experts for the purpose of developing an evidence 
based screening tool to be used for children and adolescents with CF aged 2 to 20 years . 
Catherine McDonald, PhD , RD, was then given the responsibility to develop the actual 
tool and solicit feedback from other clinical nutrition experts. This feedback included a 
qualitative feedback questionnaire and a validation survey. The qualitative comments 
were used to edit and revise the tool. The revised tool went through a validation process 
which included three phases . The final draft was then created and validated. Results : 
The qualitative feedback questionnaire showed that clinicians felt the proposed nutrition 
screening tool was capabl e of accurately reflecting nutrition risk most of the time to some 
of the time. The validation study was still underway at the time this paper was written . 
Conclusion: The new screening tool for children and adolescents with CF will be a 
reliable , valid, and useful tool. It is anticipated that because clinical nutrition 
professionals have been involved in the development process, the screening tool will be 
widely accept ed and used. This would make it an integral part of the treatment process 
for children and adolescents with CF aged 2 to 20. 
Introduction: 
Nom1al growth is the goal for all patients with CF. These individuals often 
experience nutritional inadequacy resulting in impaired growth, suboptimal lung 
function, and decreased longevity. (1,2) It is for these reasons that early identification of 
nutritional inadequacy and intervention are needed. Nutrition screening is the first step in 
the identification process. 
The Cystic Fibrosis Foundation (CFF) recommends that patients with CF be seen 
on a routine basis , every 3 months . The CF care team has the potential of having a 
powerful and positive effect on appropriate growth and lung function. Patients' growth is 
monitored and recorded at each visit. This facilitates the identification of suboptimal 
growth and supports the provision of anticipatory counseling. Monitoring growth helps 
identify CF patients at nutrition risk. It also helps facilitate early intervention and the 
prevention of further decline. (1) 
J\n effective nutrition screening tool has 5 characteristics . (3) It must be 
applicable to the patient being screened. It is important that the nutrition screening can 
be accomplished quickly and be able to provide readily available information. Reliability 
and validity are crucial characteristics. The tool must be capable of assigning levels of 
nutrition risk consistently to patients based solely on risk factors and established 
parameters. This should occur independent from the clinician administering the screen. 
The most current screening tool used for children and adolescents with CF was 
not reliable and many felt it left too much room for clinical judgment. Another concern 
was the terminology used by the tool when assigning nutritional status. Patients were 
labeled as being "acceptable", "at-risk", or "nutritional failure" . (See Figure 1) It is for 
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these reasons that a new screening tool was developed. The CFF sponsored efforts to 
produce a new and improved nutrition screening tool for children and adolescents with 
CF aged 2 to 20 years. ( 1) 
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This paper will explain the development process of the new proposed screening 
tool. It will also provide an overview of the genetic etiology and pathophysiology 
responsible for the development of CF. Nutrition complications and recommended 
interventions will be included which support the necessity of an accurate and valid 
nutrition screening tool. 
Methods: 
The Cystic Fibrosis Foundation established a panel of experts for the purpose of 
developing an evidence based screening tool to be used for children and adolescents with 
C'F aged 2 to 20 years. Catherine McDonald, PhD, RD, was then given the responsibility 
to create a screening tool based on the literature and parameters agreed upon by the 
committee. She was responsible to create and format the actual nutrition screening tool 
and then solicit feedback from other clinical nutrition experts for further refinement. 
A team of pediatric dietitians at Primary Children's Medical Center participated 
in a trial of a preliminary screening tool. The dietitians used the nutrition screening tool 
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to screen six case studies for nutrition risk . There was a 92 .1 % agreement of assigned 
nutrition risk. This exercise was useful because it revealed weaknesses in the tool and 
pointed to areas requiring further clarification. This trial made significant contributions 
to the development of the nutrition screening tool. 
Revisions were made and the tool was distributed to 17 pediatric dietitians 
throughou t the United States . The team consisted of pediatric dietitians involved in the 
provision of nutrition care for pediatric patients with CF. These nutrition professionals 
were asked to use the screening tool on 5 to l 0 patients and then report on their 
experience through a qualitative feedback questionnaire. 
The participating clinicians reported that it took an average of 5 minutes to 
comp lete the screenin g process per patient. They also reported that they felt it was 
capab le of accurate ly assessi ng and reflecting the nutrition risk of CF children and 
adolescents most of the time to all of the time. Additional comments and suggestions 
were solicited and encouraged. They were then used to edit and revise the nutrition 
screening tool. 
A new version was then distributed to the same 17 pediatric dietitians. They used 
this dratt to screen four case studies. Three of the four case studies had an agreement of 
100% for assigned nutrition risk. The fourth had an agreement of 71 %. This error helped 
identify additional revisions necessary to ensure reliability and validity. 
The screening tool was then edited and revised producing a final draft. The 
proposed nutrition screening tool (figure 2) and an algorithm representing the 
methodology (figure 3) were included on the following pages. The final draft and 18 
case studie s were distributed to a new set of 7 registered dietitians. 
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Patient Name: Gender : Age : yr mo 
Tanner Stage : if > 9 years (F) and > 10 years (M) 
Weight for stature 
Determine current BMI percentile for gender & age (CDC BMI chart): _____ _ 
Weight velocity 
Current wt (kg):_______ Date: ____ _ 
Wt (kg) la~t clinic visit. ___ _ Date: 
Net chan ge in wt : _ _ _ ______ _ 
Number or days between we ights: __ 
Daily wt gain (gm/day) _ ______ (Round to nearest whole integer) 
Expected weight gain per day (gm/day) ______ _ 
Height velocity 
Current Ht (cm): ___ _ Date: ___ _ 
Ht (cm) ::: I year; S 2 yr prior to current visit: ____ Date : ___ _ 
Net change in ht: ___ _ 
Number of years between height measurements __ _ 
Annual height gain (cm/year) _______ (Round to nearest whole integer) 
Expected height gain per year (cm/year) _________ _ 
Expected Daily Weight Gain and Annual Height Gain 
Minimally acce ptabl e rate of we ight and height ga in when Minimally acceptable rate of weight and height gain 
BMI is equal to or greater than 50th percentile. when BMI is less than 50th percentile. 
Average rate of weight and height gain at the 10th Average rate of weight and height gain at 50th 
percentile percentile 
DAILY WEIGHT ANNUAL HEIGHT DAILY WEIGHT ANNUAL 
GAIN GAIN GAIN HEIGHT GAIN 
(gm/d) (cm/yr) ( •mid) (cm/yr) 
Age, y Males Females Males Females Age,y Males Females Males Females 
2.0-2.99 3 3 7 7 2.0-2.99 5 5 9 9 
3.0-3.99 3 3 6 6 3.0-3 .99 5 5 7 8 
4.0-4 .99 3 2 5 5 4 .0-4 .99 6 5 7 7 
5.0-5.99 3 2 5 5 5.0-5.99 7 6 7 7 
6.0-6.99 3 2 5 5 6.0-6.99 7 7 6 6 
7.0 7 .99 3 ~ 4 4 7 0-7 99 8 7 6 6 
8.0-8.99 3 3 4 4 8.0-8 .99 8 8 6 6 
9 .0-9 .99 2 3 4 4 9.0-9.99 9 8 5 6 
10.0-10 .99 3 3 4 4 10.0-10 .99 9 11 5 6 
I 1.0-11.99 3 4 4 4 11.0-11.99 11 14 5 7 
12.0-12 .99 4 I 4 3 12.0-12.99 15 14 6 6 
13.0-13.99 4 < I 4 I 13.0-13 .99 18 11 8 3 
14.0-14 .99 4 < l 3 <l 14.0-14 .99 19 7 7 2 
15.0- 15.99 < I < I 1 < I 15.0-15 .99 13 4 4 1 
16.0-16 .99 <l < 1 < 1 <1 16.0-16.99 8 4 2 < l 
17.0- 17.99 < l < I <l <1 17.0-17.99 5 2 I < 1 
18.0 - 18.99 4 2 .5 . l 18.0-18 .99 5 3 .4 .1 
19.0 - 19.99 3 I .2 .I 19.0-19.99 4 3 .2 . I 
Nutrition Risk: 
0 Points I Point 2 Points 
BMI Percentile > 50%tile <50 & :::'.. 10 ¾tile _::: I0¾tile 
Daily Weight Gain > minimum > 0 & < minimum No wt ain/ Wt loss 
Annual Height Gain > minimum >0 & < minimum No ht gain 
Total Points: Nutrition Risk: 
Figure 2 . Proposed Nutrition Screening Tool for Children and Adolescents aged 2 to 20 . 
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Step 1. Assign risk points. 
for BMI Percentile 
> 50%tile 
0 point 
<50 & > 10 %tile 
1 point 
::: 1 0¾tile 
2 points 
Step 2. Assign risk points 
for daily weight gain. 
Minimally acceptable 
weight ga in detennined by 
BM! %tile, age and gender. 
Sec Table I 
Wt gain 2: minimum 
0 point 
Step 3. Assign risk points for 
annual height gain. 
Minimally acceptable height 
gain dctennined by BMI 
%tile , age and gender. See 
Table 1 NOTE: Omit this 
category if child is Tanner 
stage V, female > 15 yr or 
male> 17 yr. 
I It ga in 2: m inimum 
0 point 
Step 4. Tally total risk 




Wt gain > 0 & < minimum 
1 point 
Ht gain >0 & < minimum 
I point 
No wt gain/ Wt loss 
2 points 
No ht gain 
2 points 
Step 5. Determine nutrition risk category 
Risk points Nutrition Risk 
0 No identified factors 
1 Low 
2-3 Moderate 
> 4 High 
, . . 
Results: 
Th e qualitative feedback questionn aire showed that clinicians felt it was capable 
of accurately reflecting nutrition risk most of the time to some of the time. The 
validation of the final draft had not been completed when this paper was written . 
Discussion: 
Cystic fibrosis (CF) is the most common autosomal recessive disorder affecting 
the Caucasian population. [t affects 1 in 2,500 live births. The median life expectancy 
for thusc affected with this disease is 35 .2 years. The first publication in the United 
States describing CF was in 1938 , and the underlying genetic basis was not presented 
until 1989. CF is caused by genetic mutations in the cystic fibrosis tansmembrane 
regulator (CFTR) gene which results in defective chloride channels, causing the 
formation of excess ive mucous in the lungs and the gastrointestinal system . This mucous 
has several nutrition related conseq uence s, such as, nutrient malabsorpti on and 
malnutriti on, fat solubl e vitamin defici ency, osteoporosis, CF related diabetes , impaired 
lung function , decreased quality oflife, and early death. (2) 
Genetic Etiology: 
CF is an autosomal recessive disease. It results from a mutation in the cystic 
fibrosis tansmembran e regulator (CFTR) gene. The CFTR gene is a single large gene 
located on chromosom e 7q. It encodes for the CFTR protein. This protein is composed 
of 1480 amino acids. It functions as an integral part of chloride channels located on the 
surface of epithelial cell membranes. These cAMP regulated channels assist in the 
regulation of chloride and sodium transport. (2,4) 
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CF is due to a mutation or mutations in the CFTR gene. There have been more 
that 1200 sequence changes identified which result in clinical disease. The type of 
sequence change and resulting genetic mutation dictates the severity of the disease. 
There are four classes of CFTR gene mutations: 
1. Defective protein production: Premature termination of the mRNA can result 
from a splice-site , frameshift, or nonsense mutation. The result is a complete 
absence of the CFTR protein. 
2. Defective protein processing: The CFTR protein is unable to locate and attach 
to the correct cellular location. 
3. Defective regulation: The protein has decreased channel activity in response 
to ATP. 
4 . Dcf'cctive conduction: The protein is produced and attached correctly to the 
cell surface. Chloride currents are generated in response to cAMP 
stimulation . The mutations cause a reduction in the rate of ion flow and the 
duration of channel opening . (4) 
Pathophysiology: 
The exocri ne glands are mo st affected by the genetic mutations in the CFTR 
prot ein. Alte red sodium and chloride channel regulation leads to abnormal physical and 
chemical secretions . This abnormality manifests itself in the respiratory tract, sweat and 
salivary glands, pancreas, intestine, liver, and reproductive tract. These systems produce 
abnonnally thick mucus which obstructs glands and ducts. 
Impaired lung function is one of the biggest obstacles patients with CF face. 
Malfunctions in the CFTR protein result in defective cAMP dependent chloride secretion 
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from the respiratory epithelium. This failure of CFTR-mediated regulation of chloride 
channel activity leads to increased airway lumen absorption of sodium. The result is an 
alteration in airway secretions, which are thick and difficult to clear. 
In addition to congestion , the high chloride concentration of epithelial secretions 
may also leave the patient more susceptibl e to infection with unique bacteria. 
Pseudomonas aeruginosa, Haemophilus influenzae , and Staphylococcus aureus species 
are some of the most commonly observed infections. This increased risk of infection is 
thought to be due to the dependency of neutrophils and beta-defensins on normal chloride 
concentrations. (4) 
Abnonnal inflammation is another pulmonary related issue experienced by 
patients with CF. The CFTR-expressing tissue from patients with CF has been analyzed. 
Researchers have found that these tissues have altered fatty acid metabolism. The result 
is elevated arachidonic acid and its metabolites . It is thought that these may contribute to 
the abnorm al inflammation which is characteristic of CF. (5) 
In addition to pulmonar y complication s, CF patients often experience malfunction 
within their digestive system. The thick mucus acts as a plug preventing and limiting 
pancreatic secretions into the small intestine . The blockage decreases the amount of 
pancreatic enzymes which are able to reach the small intestine, causing enzyme 
insufficiency and maldigestion of food . The ultimate result is malabsorption and 
malnutrition. It is estimated that 85% to 90% of the CF population experiences 
pancreatic insufficiency . (1,2) 
Proper management of gastrointe stinal and pulmonary symptoms makes normal 
weight and/or growth status achievable for individuals with CF. Another important 
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factor which helps support appropriate growth is adequate nutrient and energy intake. 
There are also psychosocial and financial issues which must be properly managed. 
Malnutrition is observed when there is a discrepancy between nutrition needs and actual 
dietary intake. (6) In 2004 , 23% of U.S. children with CF were less than the 10th 
percentile weight for age and gender, and 22% of adults with CF aged 18 to 30 years are 
below a body mass index (BMI) of 19. These statistics were found in the 2004 CFF 
Patient Registry Report. (7) 
There is evidence from population based studies indicating that normal weight-
for-age, weight-for-height , and height-for-age percentiles are associated with better FEVI 
and longc\ ity f'or adults and children with CF. (2) It is recommended that children with 
CF strive to maintain nonnal weight and stature-for-age and gender. Adults should strive 
to maintain normal weight-for-height. (2) 
The CFF has made the following recommendations : 
1. Individuals with CF should consume energy intakes 110 to 200% of standard 
energy needs for the healthy general population . These elevated energy 
recommendations are necessary to support weight gain at an age-appropriate rate. 
2. Children with CF aged 1 to 12 years at risk for or with growth deficits should 
receive intensive treatment including behavioral intervention in conjunction with 
nutrition counseling. 
3. Nutritional supplements (oral and enteral) should be given to children with CF 
who experience growth deficit s and adults who experience weight deficits . This 
supplementation will improve the rate of weight gain. ( 6) 
Conclusion: 
The CFF recently identified nutrition status as the leading indicator of lung 
function and longe vity. ( 1,6) ;\ regist ered dietitian is a fundamental part of the CF care 
team. ( l) Increased attention and efforts should be given to improving the nutrition status 
of individuals with CF. Improved nutrition means improved lung function , longevity, 
and quality of life. 
The new screening tool for children and adolescents with CF will be a reliable, 
valid , and useful tool. This is because the values and parameters are evidence based and 
have been approv ed by a multidi scipline panel of experts. It is anticipated that because 
nutrition clinicians have been involved in the development process, the screening tool 
will be widely accepted and used. This would make it an integral part of the treatment 
process for children and adolescents with CF. 
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